"The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approv"...
Adverse reactions in decreasing order of severity are: bone marrow depression, with aplastic anemia, with agranulocytosis or with thrombocytopenia may occur in patients receiving long-term therapy. Peripheral neuritis, purpura, myopathy, loss of hair, and reversible azoospermia have also been reported.
Vomiting, diarrhea, and nausea may occur with colchicine therapy, especially when maximal doses are necessary for a therapeutic effect. To avoid more serious toxicity, the drug should be discontinued when these symptoms appear, regardless of whether or not joint pain has been relieved.
Dermatoses have been reported. Hypersensitivity reactions may occur infrequently.
Read the Colchicine (colchicine) Side Effects Center for a complete guide to possible side effects
Colchicine is inhibited by acidifying agents. The action of colchicine is potentiated by alkalinizing agents.
Response to sympathomimetic agents' may be enhanced by colchicine.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/4/2010
Additional Colchicine Information
Colchicine - User Reviews
Colchicine User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options